EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Radiopharm Theranostics Limited (RADX) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Radiopharm Theranostics Limited $1.26, price $1.42, upside -11.3%, quality 33 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ADR · Home Australia · ISIN US75041J1016

RT Radiopharm Theranostics Limited logo Thin data Sep 13, 2026

Radiopharm Theranostics Limited

RADX · US

Weak valuationQuality is weak on top of the rich price.

!Fair value $1.26 · Overvalued (−11.3%)
!Quality 33/100
!Expensive Growth (revenue 3y +110.0 %/yr)
!negative free cash flow
!Trails peers (1/5)
!Narrow moat 6/100
!Insider activity 45/100
!Evidence only low, so the estimate is less certain
Watch Radiopharm Theranostics Limited American Depositary Shares for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$18.90 $1.42 Fair Value $1.26 Dec 2024 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.

How to read this chart

22‑month range $1.42 – $18.90 · fair‑value band $0.8300 – $1.58 · the $1.42 price screens above the $1.26 fair value. Dashed = 300-day average. As of Sep 13, 2026.

Follow Radiopharm Theranostics Limited American Depositary Shares in your weekly email

Every Wednesday you see whether Radiopharm Theranostics Limited American Depositary Shares is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs.

Show more

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.

Stock analysis

Radiopharm Theranostics Limited American Depositary Shares (RADX) currently trades at $1.42, while our model-based Fair Value estimate is $1.26, 11.3% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 87/100, which puts the evidence level at low.

Scenario range: $0.8300 (bear) to $1.58 (bull), the price of $1.42 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Radiopharm Theranostics Limited American Depositary Shares reported revenue of A$2.7M in FY2026 versus A$8.8K in FY2022, a compound +318.4%/yr. Reported net income was −A$53.9M in FY2026.

Key figures

Market cap $21.6M · P/S ratio 1.60 · EPS (TTM) $−3.55 · Return on equity −175% · Return on assets (EBIT) −55.2% · Operating margin −357% · Revenue growth (YoY) −27.6% · Free cash flow −A$36.6M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).

What moves the price

The share trades about 87% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −11%, RADX screens richer than that median.

Fair Value models

Bear $0.8300 Fair Value $1.26 Bull $1.58
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.5900 $0.7900 $1.18 51
All 1 models by family
Asset-Based
NCAV (Graham) $0.5900 $0.7900 $1.18 51

Open the full fair value analysis →

Notify me when RADX reaches fair value

Put RADX on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 33/100

Of which business quality 34 · Market factors (momentum, volatility) 12

Profitability 0
Margins and returns on capital today
Quality Growth 10
Are margins and returns improving?
Cashflow 10
Earnings quality: real cash, not paper profit
Fin. Strength 45
Balance sheet, leverage, solvency risk
Investment 67
Disciplined investing over empire-building
Low Volatility 40
Calm price path (market factor)
Momentum 0
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 100
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 32/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−25.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+110.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−225,527.7% (2022) → −2,468.6% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

RADX screens overvalued: fair value 11% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Radiopharm Theranostics Limited American Depositary Shares with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks

Beats the industry median on 0/3 measures
Overall it trails its industry peers.
Valuation
Quality Score 34 · Below median
Profitability
Return on assets −44.6% · Bottom 25%
Growth and dividend
Revenue growth −27.6% · Bottom 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Radiopharm Theranostics Limited American Depositary Shares · Fair Value
$1.26 −11%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Radiopharm Theranostics Limited American Depositary Shares Fair Value". https://www.fairvalue-calculator.com/stock/RADX

Frequently asked questions

Is Radiopharm Theranostics Limited (RADX) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of $1.26 versus a price of $1.42, about −11% upside (overvalued).
What is the fair value of RADX?
Our model-based fair value for Radiopharm Theranostics Limited American Depositary Shares is $1.26 (as of Sep 13, 2026), built from audited fundamentals. The current price: $1.42.
What is the quality score of RADX?
Radiopharm Theranostics Limited American Depositary Shares has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Radiopharm Theranostics Limited (RADX)?
Our model-based price target is the fair value of $1.26 (as of Sep 13, 2026) from 1 valuation models. Cautious scenario $0.8300, optimistic scenario $1.58. It is a calculation from audited fundamentals, not an analyst target.
What is the Radiopharm Theranostics Limited American Depositary Shares stock forecast for 2026?
Our models put fair value at $1.26, about −11% upside versus a price of $1.42 (overvalued). Cautious scenario $0.8300, optimistic scenario $1.58. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Radiopharm Theranostics Limited (RADX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Radiopharm Theranostics Limited American Depositary Shares it is $1.26 per share (as of Sep 13, 2026), against a price of $1.42. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Radiopharm Theranostics Limited American Depositary Shares stock overvalued or undervalued in 2026?
As of Sep 13, 2026, RADX trades above its calculated fair value: price $1.42, fair value $1.26, a gap of about −11% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RADX?
No. The price is what the market pays today ($1.42); the fair value is what the company's own numbers justify ($1.26). For Radiopharm Theranostics Limited American Depositary Shares the two are $0.1600 per share apart. That gap is exactly why we show both numbers side by side.
How much is Radiopharm Theranostics Limited American Depositary Shares worth?
The market values Radiopharm Theranostics Limited American Depositary Shares at about $21.6M (market capitalisation, as of Sep 13, 2026). Per share that is $1.42; our models calculate a fair value of $1.26 per share.
What do the bullish and bearish scenarios say about RADX?
Our models span a range for Radiopharm Theranostics Limited American Depositary Shares: cautious scenario $0.8300, base $1.26, optimistic $1.58 per share (as of Sep 13, 2026, price $1.42). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Radiopharm Theranostics Limited (RADX)?
Balance-sheet figures for Radiopharm Theranostics Limited American Depositary Shares (as of Sep 13, 2026): return on equity −174.7%. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is RADX from its 52-week high?
Radiopharm Theranostics Limited American Depositary Shares trades at $1.42, about 87% below its 52-week high of $10.63 and at the low of $1.42 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $1.26 is for.
Which stocks are comparable to Radiopharm Theranostics Limited American Depositary Shares?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Radiopharm Theranostics Limited American Depositary Shares stock attractive at the current price?
The data as of Sep 13, 2026: price $1.42, calculated fair value $1.26 (−11%), Quality Score 33/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RADX calculated?
We run Radiopharm Theranostics Limited American Depositary Shares through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.26, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Radiopharm Theranostics Limited American Depositary Shares itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Radiopharm Theranostics Limited (RADX)?
The closing price on Oct 2, 2026 was $1.42. Our model-based fair value is $1.26, about −11% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Radiopharm Theranostics Limited American Depositary Shares right now?
A fairly wide model range ($0.8300 to $1.58) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Radiopharm Theranostics Limited American Depositary Shares

How large is the market capitalisation of Radiopharm Theranostics Limited (RADX)?
The market capitalisation of Radiopharm Theranostics Limited American Depositary Shares is $21.6M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Radiopharm Theranostics Limited (RADX)?
The price-to-sales ratio of Radiopharm Theranostics Limited American Depositary Shares is 1.60 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Radiopharm Theranostics Limited (RADX)?
Earnings per share at Radiopharm Theranostics Limited American Depositary Shares are $−3.55. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Radiopharm Theranostics Limited (RADX)?
The return on equity (ROE) of Radiopharm Theranostics Limited American Depositary Shares is −175% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Radiopharm Theranostics Limited (RADX)?
On an EBIT basis the return on assets of Radiopharm Theranostics Limited American Depositary Shares is −55.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Radiopharm Theranostics Limited (RADX)?
The operating margin of Radiopharm Theranostics Limited American Depositary Shares is −357% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Radiopharm Theranostics Limited (RADX)?
Revenue at Radiopharm Theranostics Limited American Depositary Shares is growing −27.6% versus a year earlier (3y avg +110%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Radiopharm Theranostics Limited (RADX) generate?
The free cash flow of Radiopharm Theranostics Limited American Depositary Shares is −A$36.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Radiopharm Theranostics Limited (RADX) hold?
Radiopharm Theranostics Limited American Depositary Shares holds more cash than debt, A$4.1M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Radiopharm Theranostics Limited American Depositary Shares in the live analysis

One click puts Radiopharm Theranostics Limited American Depositary Shares on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.